SURVEY AND SUMMARY
The ageing mitochondrial genome

Kim J. Krishnan*, Laura C. Greaves, Amy K. Reeve and Doug Turnbull

Mitochondrial Research Group, School of Neurology, Neurobiology and Psychiatry and Institute for Ageing and Health, Newcastle University, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK

Received July 6, 2007; Revised August 2, 2007; Accepted August 2, 2007

ABSTRACT
The population of elderly individuals has increased significantly over the past century and is predicted to rise even more rapidly in the future. Ageing is a major risk factor for many diseases such as neurodegenerative disease, diabetes and cancer. This highlights the importance of understanding the mechanisms involved in the ageing process. One plausible mechanism for ageing is accumulation of mutations in the mitochondrial genome. In this review, we discuss some of the most convincing data surrounding age-related mtDNA mutations and the evidence that these mutations contribute to the ageing process.

INTRODUCTION
Throughout the lifetime of an organism, the production of energy is a fundamental requirement. The majority of this energy, in the form of ATP, is produced through the process of oxidative phosphorylation (OXPHOS); the complexes involved are situated in the inner mitochondrial membrane. Mitochondria are intracellular organelles that contain their own DNA (mtDNA), which is distinct from nuclear DNA and can be replicated independently of the cell cycle. This allows the production of more mtDNA molecules capable of producing proteins for OXPHOS under high-energy demands. There is a small, ∼1 kb non-coding control region on the mitochondrial genome, but apart from this, the rest of the 16.5 kb genome is entirely transcribed. The mitochondrial genome codes for 37 genes, which includes 13 essential polypeptides of the OXPHOS system, 22 tRNAs and 2 rRNAs which are required for intramitochondrial protein synthesis. The vast majority of the proteins involved in OXPHOS are encoded by nuclear DNA, translated in the cytoplasm and imported into the mitochondria.

MtDNA is present in multiple copies within each cell; the actual number varies between cell type and on the energy demands within each tissue. The multi-copy nature of mtDNA means that any mutations occurring on the mitochondrial genome can exist amongst wild-type copies in a situation referred to as heteroplasmy (1). These mutant copies do not exert a biochemical phenotype on a cell until the mutant copies reach a certain level. This threshold of mutant: wild type can vary depending on the specific mutation and on cell type. The types of mtDNA mutations which can occur vary from single point mutations to large-scale rearrangements such as deletions and duplications (1). Mutations on the mitochondrial genome are thought to arise due to the close proximity of mtDNA to the OXPHOS system located on the inner mitochondrial membrane, making the mitochondrial genomes vulnerable to damage through the leakage of reactive oxygen species (ROS) during the OXPHOS process. Mitochondria are able to counteract the production of ROS with antioxidant defence systems which can detoxify the amount of ROS produced, however some ROS do evade these processes and are able to damage mtDNA as well as proteins and lipids. MtDNA molecules are contained within nucleoids, which contain essential maintenance proteins including the mitochondrial transcription factor A gene (TFAM) which effectively coats the mtDNA molecule. However, it is uncertain whether this offers any protection against ROS, and this along with limited repair capacity means that there is a high mutation rate. This increased susceptibility of mtDNA to ROS leading to mutations has led to the proposal of the mitochondrial theory of ageing (2,3). This theory suggests that damaged mitochondrial genomes lead to inefficient OXPHOS causing the production of more ROS which will further damage the mtDNA, resulting in a so-called ‘vicious cycle’.

Evidence for accumulation of mtDNA mutations with age
In support of a role for mtDNA mutations in ageing, both mtDNA point mutations and deletions have been described to accumulate on the mitochondrial genome with age in a variety of tissues (4–8). High levels of a m.414T>G transversion was found in fibroblasts from half of subjects older than 65 years but was absent from all younger individuals (6). The m.414T>G mutation has most recently been shown to occur significantly more
frequently in fibroblasts taken from skin from sun-exposed skin sites suggesting that increased oxidative stress through ultraviolet (UV) radiation exposure results in the production of this mutation (9). The absence or marginal presence of the m.414T>G mutation in skeletal muscle, brain, heart, lymph nodes and spleen has led to the suggestion that it may be tissue specific (10–12). Suggestions of tissue-specific ‘hot-spots’ for point mutations on the mitochondrial genome have also been described (13), with the clonal expansion of point mutations accumulating with age in cardiomyocytes and buccal epithelium, but the distribution of these point mutations were described to be significantly different. The region 407–411 of mtDNA which is close to the age-associated m.414T>G mutation has also been suggested as being a hot-spot for mutations in muscle mtDNA (12). Work in our own laboratory on colonic epithelium has shown an age-dependent increase of clonally expanded point mutations, with ~50% of colonocytes taken from aged patients harbouring a point mutation (7). However we have not observed any evidence for specific mutation ‘hot-spots’, with the distribution of the point mutations spread throughout the genome (7).

The age-related accumulation of mtDNA deletions has also been described. The initial observations were focused on a well-characterized 4977 bp deletion, the so-called ‘common deletion’. This deletion had previously been identified in a number of patients with mitochondrial disease (Kearns Sayre syndrome and chronic progressive external ophthalmoplegia). Studies on tissues from normal subjects showed that the common deletion was detectable in heart muscle, skeletal muscle, brain and other tissues of older human subjects, but not from the same tissues from young individuals (14–16). Technical difficulties in the study of mtDNA deletions resulted in the majority of early studies focussing on identifying single deletions in ageing tissues, such as the common deletion and the levels detected even in tissues from very elderly individuals rarely exceeded ~1%. Thus, it was thought that these very low levels of mtDNA deletions associated with ageing were unlikely to contribute to the ageing process. However it was shown that if mtDNA mutations accumulate to high levels focally in a small subset of cells, then this leads to cells which have respiratory chain deficiency, detected by an absence of staining for cytochrome c oxidase (COX) activity (17,18).

Respiratory deficient cells have since been shown to accumulate with age in a number of tissues (4,7,19) (Figure 1). Also, it was apparent that the common deletion was only one of several different possible deletions present in ageing human tissues and the development of single-cell-based PCR techniques allowed the measurement of all deletions in single cells. Recently, we and colleagues were the first to report the age-related accumulation of mtDNA deletions to very high levels (~50%) in substantia nigra neurons from both normal controls and individuals with Parkinson’s disease (4,5). Analysis of mtDNA deletions using long-range PCR in individual neurons showed that each neuron harboured a different mtDNA deletion usually consisting of just one type, which suggests that these mtDNA deletions arose through clonal expansion (see later) (Figure 2). Respiratory chain-deficient neurons had significantly higher level of mtDNA deletions than neurons with normal COX activity, supporting the hypothesis that these deletions were the cause of the respiratory chain deficiency. Similar observations have also been made by analysing ageing muscle fibres. These studies also showed that in age-related respiratory chain-deficient fibres there was clonal expansion of mtDNA deletions, with over 80% of mtDNA in the affected fibres harbouring a clonally expanded deletion (20).

Are mtDNA mutations important in human ageing?

In humans, the increase in mtDNA mutations with age does not prove that they have a role in the ageing process;
Rhesus monkeys was shown to correlate in those sections subjects (30). Atrophy in skeletal muscle fibres from sarcopenia, which is a common feature in aged human mutations in age-related cellular degeneration has been deletions have on the normal functioning of the skin. It is unknown at present what effects these mtDNA support the theory that increased oxidative stress results in mtDNA damage and the production of mutations. These observations provide a strong association that mtDNA deletions contribute to the age-related decline of muscle mass and function.

The age-associated accumulation of high levels of mtDNA deletions in the dopamine producing, pigmented neurons of the substantia nigra is additional support for a role of mtDNA mutations in the ageing process. This region of the brain loses neurons at a rate of ~5% per decade (34) and there is an even greater neuronal loss in patients with Parkinson’s disease. It is unknown at present whether the age-related loss of neurons in the substantia nigra is due to the accumulation of mtDNA deletions in these neurons. However, mtDNA dysfunction resulting from reduced mtDNA expression has been shown to cause a parkinsonian phenotype in mice (35). The cause of the reduced mtDNA expression in these mice is due to selective knockout of TFAM in dopamine producing neurons within the substantia nigra. The mice had respiratory chain deficiency accompanied by cell loss, selectively in this region and provides support that normal mtDNA expression is crucial for the functioning and viability of neurons within the substantia nigra. Recent studies have also shown that substantia nigra neurons have an unusual reliance on certain calcium channels to maintain their pacemaker currents and this seems likely to make them particularly sensitive to mitochondrial dysfunction (36).

**Ageing mouse model**

A major advance in the support for a direct role of mtDNA mutations in the ageing process was demonstrated by two groups who created mice with a premature ageing phenotype due to knock-in mutations in the exonuclease domain of polymerase gamma (POLG) (37,38). POLG is the only known polymerase to be targeted to mitochondria and as such is thought to be solely responsible for the maintenance of all aspects of mtDNA including replication and repair. In humans, POLG is a heterotrimeric enzyme consisting of a catalytic subunit (POLGA) and two identical accessory subunits (POLGB) (39). Therefore it was no surprise that a mutation in the exonuclease domain (proofreading) of POLGA resulted in the mice having increased mtDNA mutation rates as detected by cloning analysis (38). Some controversy exists over the validity of the mutation rates detected by the cloning methodology and a recent paper has re-analysed the mutation rates in the POLG mice using a random capture methodology (RMC) suggesting the mutation rates calculated by the cloning method are too high (40). However, even using the RMC method, the mutation rates of the POLG mice are higher than their wild-type counterparts.
A surprising observation in the POLG mice is that there is no evidence of increased ROS production (41), which is predicted by the mitochondrial theory of ageing. In addition, mRNA levels of antioxidant defence systems were unaffected, suggesting a lack of a ROS-induced stress response. The authors question the role of ROS in the premature ageing symptoms displayed by these mice and suggest that the respiratory chain deficiency may be the major factor involved in the age-associated decline in function, presumably caused through the generation of increased mtDNA mutations. An alternative explanation is that the generation of mtDNA mutations through inefficient POLG may be downstream from mechanisms that generate ROS (42). Therefore, it is possible that ROS can induce mtDNA mutations directly or through damaging POLG to make it error-prone, but the resulting mtDNA mutations do not increase the production of ROS. To further confuse the role of ROS in ageing is the observation that high oxidative damage levels are observed in the longest-living rodent, the naked mole rat (43). It has also been reported that heterozygous SOD2 knockouts have increased oxidative damage but normal lifespan (44). All these results seem to contradict the simplest assumption that increased ROS production promotes accelerated ageing. However, these results may be an indication that as discussed previously, other factors such as the nuclear genetic background play a crucial role in the susceptibility to the effects of increased oxidative damage.

Clonal expansion of mtDNA mutations

Whilst there remains some controversy over the best method to measure mutation rates, in terms of respiratory chain deficiency (and possibly ageing) the crucial factor in determining dysfunction is the clonal expansion of the mtDNA mutation within a cell. Clonal expansion of a specific mtDNA mutation has been described by many different authors in both disease and ageing tissues (4,5,7,13,20,45). In patients with primary mtDNA defects, the clonally expanded mutation is identical between different cells, whereas in ageing different mutations are seen in adjacent cells. In ageing it seems likely that the mutation was derived from a single event and this mutation subsequently expands to become the predominant species within an individual cell. The precise mechanism of clonal expansion is unknown, but several authors have proposed a random genetic drift model (46).

An important research focus should be to understand the mechanism of clonal expansion in different tissues, especially post-mitotic tissues where the rate of replication of the mitochondrial genome is uncertain. Unfortunately, at present, methods to determine rates of mtDNA replication cannot be differentiated from those measuring repair. In post-mitotic tissues, DNA repair is an active process and may even be involved in the generation of mutations. Secondary defects are those due to mutations in nuclear genes involved in mtDNA maintenance. These patients present with a variety of different clinical features, particularly involving tissues heavily dependent upon OXPHOS. These patients have been crucial in our understanding of human mitochondrial genetics, but also provide important clues as to the potential role of mtDNA in the ageing process. These include:

(i) The concept of threshold for an individual mtDNA mutation leading to respiratory chain deficiency in an individual cell. This phenomenon is crucial to understanding the importance of clonal expansion in ageing tissues. Indeed an important part of the diagnosis of mtDNA mutations is that these mutations have to show a threshold to confirm the pathogenic nature of any specific point mutation. This confirms again the importance of clonal expansion of somatic mutations before a biochemical defect is seen.

(ii) MtDNA mutations lead to human pathology. In patients with mtDNA mutations, there is both clinical disease and evidence of cell loss and dysfunction. These changes are much more marked than those seen with ageing but are still relevant since we believe the respiratory chain-deficient cells are essentially the same in both mtDNA disease and ageing.

The clinical features of patients with mtDNA disease are very different from ageing although this is not surprising since these patients are born with high levels of a single mtDNA mutation. The phenotype will depend upon both the nature of the mtDNA mutation and the level in a number of different tissues. More relevant to ageing are those patients with primary nuclear mutations involved in mtDNA maintenance. These patients acquire mtDNA mutations throughout life, often mtDNA deletions. This is clearly similar to the observations in post-mitotic tissues in ageing individuals. The level of mtDNA mutations is much greater in tissues than seen in ageing since there is often severe disease leading to disability or death. Genetic defects of POLG are the most important of the defects leading to secondary mtDNA defects (47). Interestingly one of the phenotypes seen in these patients is Parkinsonism associated with loss of cells in the substantia nigra and high levels of deleted mtDNA (48–50). This is remarkably similar to recent observations in elderly tissues and confirms that defects of mtDNA can lead to cell loss in this region of the brain.

Whilst patients with either primary or secondary defects of mtDNA do not present good phenotypic models of human ageing, they do show that these genetic defects of the mitochondrial genome can lead to pathology and thus are supportive of a role of mtDNA mutations in human ageing.

Cell death

The ultimate insult that mtDNA mutations could have on a cell would be to impair the function so much as to lead to cell death. It is well known that mitochondria are
central players in apoptosis, or programmed cell death. Therefore, if high levels of mtDNA mutations lead to mitochondrial dysfunction, it seems possible that this will compromise the cell and result in apoptosis. Respiratory chain deficiency, caused by reduced mtDNA expression, has been shown to be associated with increased apoptosis in TFAM knockout animal models (51). Mitochondrial dysfunction, induced by a variety of oxidative stresses has been shown to induce apoptosis in cultured neurons and cardiomyocytes (52–54), but evidence of underlying mtDNA mutations as the cause was not investigated in these studies. However, cleaved caspase-3 an indicator of apoptosis, was increased in a variety of tissues in the POLG mice (37), suggesting that the increased mtDNA mutation load in these animals could be responsible for the decline in tissue function with age. It has also been recently reported that genes involved in apoptosis are upregulated in the cochlear of the POLG-mutated mice and therefore the resulting effect could be the age-related hearing loss in these mice (55). In addition increased TUNEL staining was observed in the hippocampus in mitochondrial late-onset neurodegeneration (MILON) mice (56), which are mice with mtDNA depletion due to a knockout of TFAM. The TUNEL staining in these MILON mice was often observed before any obvious cell loss.

CONCLUSIONS
In this review, we have shown that there is increasing evidence to suggest that the accumulation of mtDNA mutations with age could play a role in the decline in cellular function within many tissues. We have summarized some of this evidence in Figure 3, which shows that mtDNA mutations could be caused by either replication errors or increased oxidative stress, if a mutated mtDNA molecule is then allowed to replicate and clonally expand within a cell, this cell may become respiratory chain deficient. This compromised energy production could lead to the demise of the cell, and if substantial cell loss is observed this may result in tissue dysfunction and the onset of ageing. If this is correct then by preventing the mtDNA mutations from arising should increase lifespan. Support for this theory has already been shown with the observation of an increase in lifespan of mice over-expressing human catalase localized to mitochondria (57). These mice had reduced cardiac pathology and cataract onset of ageing. If this is correct then by preventing the demise of the cell, and if substantial cell loss is observed should increase lifespan. Support for this theory has already been shown with the observation of an increase in lifespan of mice over-expressing human catalase localized to mitochondria (57). These mice had reduced cardiac pathology and cataract onset of ageing. If this is correct then by preventing the demise of the cell, and if substantial cell loss is observed should increase lifespan. Support for this theory has already been shown with the observation of an increase in lifespan of mice over-expressing human catalase localized to mitochondria (57).

Figure 3. Schematic diagram displaying how mtDNA mutations could lead to the ageing process and the major evidence in the literature to support this role.

to be tissue-specific differences and influence on these processes of nuclear genetic factors.

ACKNOWLEDGEMENTS
We are grateful for support from the Alzheimer’s Research Trust, Food Standards Agency (UK), The Wellcome Trust and the Medical Research Council. Funding to pay the Open Access publication charges for this article was provided by The Wellcome Trust.

Conflict of interest statement. None declared.

REFERENCES
1. Taylor, R.W. and Turnbull, D.M. (2005) Mitochondrial DNA mutations in human disease. Nat. Rev. Genet., 6, 389–402.
2. Harman, D. (1972) The biology clock: the mitochondria? J. Am. Geriatr. Soc., 20, 145–147.
3. Linnane, A.W., Marzuki, S., Ozawa, T. and Tanaka, M. (1989) Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet, 1, 642–645.
4. Bender, A., Krishnan, K.J., Morris, C.M., Taylor, G.A., Reeve, A.K., Perry, R.H., Jaros, E., Hersheson, J.S., Betts, J. et al. (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet., 38, 515–517.
5. Kraysberg, Y., Kudryatseva, E., McKee, A.C., Geula, C., Kowall, N.W. and Khrapko, K. (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet., 38, 518–520.
6. Michikawa, Y., Mazzucchelli, F., Bresolin, N., Scarlato, G. and Attardi, G. (1999) Aging-dependent large accumulation of point
7404 Nucleic Acids Research, 2007, Vol. 35, No. 22

mutations in the human mtDNA control region for replication. Science, 286, 774–777.

7. Taylor,R.W., Barron,M.J., Borthwick,G.M., Gospel,A., Chinnery,P.F., Samuels,D.C., Taylor,G.A., Plusa,S.M., Needham,S.J. et al. (2003) Mitochondrial DNA mutations in human colonic crypt stem cells. J. Clin. Invest., 112, 1351–1360.

8. Corral-Debrinski,M., Lipkin,W.I., Boney,M.L., Shoffner,J.M., Lott,M.T. and Wallace,D.C. (1995) Association of mitochondrial DNA mutations with aging and central nervous system disease. Ann. NY Acad. Sci., 774–779.

9. Chinnery,P.F., Taylor,G.A., Howell,N., Brown,D.T., Parsons,T.J. and Turnbull,D.M. (2001) Point mutations of the mtDNA control region in normal and neurodegenerative human brains. Am. J. Hum. Genet., 68, 529–532.

10. Corral-Debrinski,M., Horton,T., Lott,M.T., Shoffner,J.M., Nekhaeva,E., Bodyak,N.D., Kraytsberg,Y., McGrath,S.B., Van Corveld,E.H., Borthwick,G.M. and Van der Schouw,Y.T. (2001) Mitochondrial DNA mutations in human skin. Proc. Natl Acad. Sci. USA, 98, 4022–4027.

11. Chinnery,P.F., Taylor,G.A., Howell,N., Brown,D.T., Parsons,T.J. and Turnbull,D.M. (2001) Mitochondrial DNA mutations and neurodegenerative disease. Nat. Med., 7, 1039–1044.

12. Wang,Y., Michikawa,Y., Mallidis,C., Bai,Y., Woodhouse,L., Meredith,G.E. and Surmeier,D.J. (2007) ‘Rejuvenation’ protects individual cells of human tissues. J. Appl. Physiol., 102, 318–323.

13. Nekhaeva,E., Bodyak,N.D., Kraytsberg,Y., McGrath,S.B., Van Oers,M.J., Pluzhnikov,A., Wei,J.Y., Vieg.J. and Khrapko,R. (2002) Clonally expanded mtDNA point mutations are abundant in individual cells of human tissues. Proc. Natl Acad. Sci. USA, 99, 5521–5526.

14. Corral-Debrinski,M., Shoffner,J.M., Lott,M.T. and Wallace,D.C. (1992) Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat. Res., 275, 169–180.

15. Cortopassi,G.A., Shibata,D., Soong,N.W. and Arheim,N. (1992) A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc. Natl Acad. Sci. USA, 89, 7370–7374.

16. Soong,N.W., Hinton,D.R., Cortopassi,G. and Arheim,N. (1992) Mosaicism for a specific somatic mitochondrial DNA mutation in human brain. Nat. Genet., 2, 318–323.

17. Brierley,E.J., Johnson,M.A., Lightowlers,R.N., James,O.F. and Timpson,N.P. (2007) Mitochondrial DNA mutations accumulate in human skeletal muscle fibers. Am. J. Hum. Genet., 79, 469–480.

18. Corbiser,P. and Remacle,J. (1993) Influence of the energetic pattern of mitochondria in cell ageing. Mech. Ageing Dev., 71, 47–58.

19. Corbiser,P. and Remacle,J. (1990) Involvement of mitochondria in cell degeneration. Eur. J. Cell Biol., 51, 173–182.

20. Yao,Y.G., Ellison,F.M., McCoy,J.P., Chen,J. and Young,N.S. (2007) Age-dependent accumulation of mtDNA mutations in murine hematopoietic stem cells is modulated by the nuclear genetic background. Hum. Mol. Genet., 16, 286–294.

21. Jou,M.J., Peng,T.L., Wu,H.Y. and Wei,Y.H. (2005) Enhanced generation of mitochondrial reactive oxygen species in cybrids containing 4977-bp mitochondrial DNA deletion. Ann. NY Acad. Sci., 1042, 221–228.
44. Van Remmen, H., Ikeno, Y., Hamilton, M., Pahlavani, M., Wolf, N., Thorpe, S.R., Alderson, N.L., Baynes, J.W., Epstein, C.J. et al. (2003) Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. *Physiol. Genomics*, 16, 29–37.

45. McDonald, S.A., Preston, S.L., Greaves, L.C., Leedham, S.J., Lovell, M.A., Jankowski, J.A., Turnbull, D.M. and Wright, N.A. (2006) Clonal expansion in the human gut: mitochondrial DNA mutations show us the way. *Cell Cycle*, 5, 808–811.

46. Elson, J.L., Samuels, D.C., Turnbull, D.M. and Chinnery, P.F. (2001) Random intracellular drift explains the clonal expansion of mitochondrial DNA mutations with age. *Am. J. Hum. Genet.*, 68, 802–806.

47. Hudson, G. and Chinnery, P.F. (2006) Mitochondrial DNA polymerase-gamma and human disease. *Hum. Mol. Genet.*, 15(Spec No 2), R244–R252.

48. Davidzon, G., Greene, P., Mancuso, M., Klos, K.J., Ahlskog, J.E., Hirano, M. and DiMauro, S. (2006) Early-onset familial parkinsonism due to POLG mutations. *Ann. Neurol.*, 59, 859–862.

49. Hudson, G., Schaefer, A.M., Taylor, R.W., Tiangyou, W., Gibson, A., Venables, G., Griffiths, P., Burn, D.J., Turnbull, D.M. et al. (2007) Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. *Arch. Neurol.*, 64, 553–557.

50. Luoma, P., Melberg, A., Rinne, J.O., Kaukonen, J.A., Nupponen, N.N., Chalmers, R.M., Oldfors, A., Rautakorpi, L., Peltonen, L. et al. (2004) Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. *Lancet*, 364, 875–882.

51. Wang, J., Silva, J.P., Gustafsson, C.M., Rustin, P. and Larsson, N.G. (2001) Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. *Proc. Natl Acad. Sci. USA*, 98, 4038–4043.

52. Hoyt, K.R., Gallagher, A.J., Hastings, T.G. and Reynolds, I.J. (1997) Characterization of hydrogen peroxide toxicity in cultured rat forebrain neurons. *Neurochem. Res.*, 22, 333–340.

53. Jang, Y.-M., Kendiah, S., Drew, B., Phillips, T., Selman, C., Julian, D. and Leeuwenburgh, C. (2004) Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. *FEBS Lett.*, 577, 483–490.

54. Keller, J.N., Kindy, M.S., Holtsberg, F.W., St Clair, D.K., Yen, H.C., Germeyer, A., Steiner, S.M., Bruce-Keller, A.J., Hutchins, J.B. et al. (1998) Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. *J. Neurosci.*, 18, 687–697.

55. Someya, S., Yamasoba, T., Kujoth, G.C., Pugh, T.D., Weindruch, R., Tanokura, M. and Prolla, T.A. (2007) The role of mtDNA mutations in the pathogenesis of age-related hearing loss in mice carrying a mutator DNA polymerase gamma. *Neurobiol. Aging.*, doi:10.1016/j.neurobiolaging.2007.01.014.

56. Sorensen, L., Ekstrand, M., Silva, J.P., Lindqvist, E., Xu, B., Rustin, P., Olson, L. and Larsson, N.G. (2001) Late-onset corticohippocampal neurodepletion attributable to catastrophic failure of oxidative phosphorylation in MILON mice. *J. Neurosci.*, 21, 8082–8090.

57. Schriner, S.E., Linford, N.J., Martin, G.M., Treuting, P., Ogburn, C.E., Emond, M., Coskun, P.E., Ladiges, W., Wolf, N. et al. (2005) Extension of murine life span by overexpression of catalase targeted to mitochondria. *Science*, 308, 1909–1911.